Rheumatic diseases are intrinsically linked to environmental conditions. With a constantly changing environment, how can rheumatologists adapt to the challenges of global climate change, pollution and other environmental threats? The Environment + Genetics Tamiko Katsumoto, MD, a clinical associate professor in the Division of Immunology and Rheumatology at Stanford University, Palo Alto, Calif., emphasizes the…
Dr. Arthur Grayzel leaves behind a legacy of care as a parent, teacher, researcher & clinician.
In an effort to ameliorate serious rheumatology provider shortages, the ACR Workforce Solutions Committee has developed a new resource for primary care providers who treat patients with rheumatic conditions.
It’s an exciting time for ultrasound in rheumatology, & it’s never too late to learn. Whether you’re just starting fellowship or have been practicing for decades, there’s a place for ultrasound in your practice.
The story of one patient whose research participation helped establish VEXAS as a diagnosable condition.
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.